Medication adherence, first episode duration, overall duration and time without therapy: The example of bisphosphonates

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 1, 2009, Pages 69-75

  Roughead, Elizabeth E ^a   Ramsay, Emmae ^b   Priess, Kym ^a   Barratt, John ^a   Ryan, Philip ^b   Gilbert, Andrew L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Adherence; Bisphosphonates; Compliance; Duration; Persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; FRAGILITY FRACTURE; HUMAN; MALE; NORMAL HUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREND STUDY; FACTUAL DATABASE; KAPLAN MEIER METHOD; STATISTICS; TIME; UNITED STATES; VETERAN;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIPHOSPHONATES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MEDICATION ADHERENCE; TIME FACTORS; UNITED STATES; VETERANS;

EID: 59049104684     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1687     Document Type: Article

References (20)

1. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006; 333: 15.
2. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574.
3. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006; 28: 1411-1424.
4. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-457.
5. Therapeutic Guidelines Ltd. e-TG complete. Therapeutic Guidelines Ltd.: North Melbourne, 2008.
6. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023-1031.
7. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification index with Defined Daily Doses. http://www.whocc.no/atcddd/ [Accessed 4 February 2004].
8. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the resupply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health 2000; 24: 603-606.
9. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006; 17: 922-928.
10. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414-2419.
11. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-861.
12. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006; 28: 1686-1694.
13. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-1022.
14. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271-287.
15. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008.
16. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922-928.
17. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82: 1493-1501.
18. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006; 22: 2383-2391.
19. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits http://www.pbs.gov.au/html/healthpro/home [Accessed 17 July 2007]
20. Australian Government Department of Health and Ageing. Australian statistics on medicines 2006 Australian Government Department of Health and Ageing: Canberra, 2008.